Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804307 | 0.94 | KMT2A (0.49) | ACECTSLTSHRKMT2ACTSV | |
| SCHEMBL6798801 | 0.92 | ACE (0.43) | ACECTSLTSHRKMT2AITGB3 | |
| SCHEMBL4454262 | 0.91 | ITGB3 (0.42) | ACECTSLTSHRKMT2AITGB3 | |
| SCHEMBL6798370 | 0.90 | GPR132 (0.42) | ACECTSLTSHRKMT2AITGB3 | |
| SCHEMBL4449534 | 0.90 | ACE (0.38) | ACECTSLTSHRKMT2AITGB3 | |
| SCHEMBL4458967 | 0.89 | CTSK (0.47) | ACECTSLTSHRITGB3ITGA2B | |
| SCHEMBL4458898 | 0.89 | ITGB3 (0.41) | ACECTSLTSHRITGB3ITGA2B | |
| SCHEMBL4452835 | 0.89 | ITGB3 (0.41) | ACECTSLTSHRITGB3ITGA2B | |
| SCHEMBL6798893 | 0.89 | CHRNA1 (0.42) | CTSLCTSSACE2GRIA1 | |
| SCHEMBL4449465 | 0.89 | ITGB3 (0.40) | ACECTSLTSHRKMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | ACE 371/4885CTSL 23/4885TSHR 3678/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | ACE 267/4885CTSL 16/4885TSHR 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.